Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2002 | 09-2002 | 06-2002 | 03-2002 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,707,900 | 1,971,600 | 1,287,700 | 629,200 | 2,780,000 |
| Depreciation Amortization | 493,000 | 393,300 | 262,700 | 131,400 | 454,900 |
| Income taxes - deferred | 346,500 | 343,400 | 390,300 | 65,400 | 273,800 |
| Accounts receivable | -321,100 | N/A | N/A | N/A | 167,500 |
| Accounts payable and accrued liabilities | -268,500 | N/A | N/A | N/A | 20,400 |
| Other Working Capital | -1,542,100 | -1,397,000 | -1,117,600 | -572,500 | -77,400 |
| Other Operating Activity | 655,000 | 64,400 | -16,600 | -15,300 | 42,400 |
| Operating Cash Flow | $2,070,700 | $1,375,700 | $806,500 | $238,200 | $3,661,600 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -651,800 | -499,400 | 4,200 | 57,000 | -520,300 |
| PPE Investments | -1,094,100 | -740,000 | -419,800 | -192,700 | -852,400 |
| Purchase Of Investment | -5,190,300 | -3,534,800 | -2,171,300 | -1,119,000 | -5,931,100 |
| Sale Of Investment | 4,777,900 | 3,210,100 | 2,430,300 | 1,136,500 | 3,708,700 |
| Other Investing Activity | -316,100 | -247,300 | -111,500 | -50,700 | -369,700 |
| Investing Cash Flow | $-2,474,400 | $-1,811,400 | $-268,100 | $-168,900 | $-3,964,800 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -18,000 | 392,900 | -8,600 | -12,800 | 102,000 |
| Debt Issued | 1,259,600 | 1,203,100 | 512,200 | 498,300 | 901,300 |
| Debt Repayment | -7,200 | N/A | N/A | N/A | -408,600 |
| Common Stock Issued | 64,600 | 48,600 | 38,800 | 27,600 | 109,500 |
| Common Stock Repurchased | -385,200 | -243,900 | -178,100 | -55,600 | -545,700 |
| Dividend Paid | -1,335,800 | -1,002,000 | -667,500 | -334,000 | -1,207,200 |
| Financing Cash Flow | $-422,000 | $398,700 | $-303,200 | $123,500 | $-1,048,700 |
| Exchange Rate Effect | 69,300 | 120,900 | 113,700 | -14,200 | -60,700 |
| Beginning Cash Position | 2,702,300 | 2,702,300 | 2,702,300 | 2,702,300 | 4,114,900 |
| End Cash Position | 1,945,900 | 2,786,200 | 3,051,200 | 2,880,900 | 2,702,300 |
| Net Cash Flow | $-756,400 | $83,900 | $348,900 | $178,600 | $-1,412,600 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,070,700 | 1,375,700 | 806,500 | 238,200 | 3,661,600 |
| Capital Expenditure | -1,130,900 | -740,000 | -419,800 | -192,700 | -884,000 |
| Free Cash Flow | 939,800 | 635,700 | 386,700 | 45,500 | 2,777,600 |